Abacus Life Reports Impressive Q3 Performance
- Continued Growth in Revenue and Profitability -
- Total Revenue Increase of 33% Year-over-Year to $28.1 Million -
- Non-Cash Warrant Liability Impacted GAAP Net Loss at $5.1 Million -
- Adjusted Net Income Surges 65% Year-over-Year to $14.9 Million -
- Adjusted EBITDA Rises 54% Year-over-Year to $16.7 Million -
Abacus Life, Inc. (NASDAQ: ABL), a leading global alternative asset manager known for its innovative approach to leveraging longevity data and actuarial technology, reported significant results for the third quarter. With a commitment to provide uncorrelated investment opportunities, the company showcased strong financial metrics for the quarter ending September 30.
CEO Jay Jackson expressed enthusiasm about the quarter, stating, "We achieved remarkable growth and maintained profitability while focusing on our long-term strategic initiatives." A notable highlight mentioned by Jackson was the advancement of their ABL Tech platform, which now serves over 20 clients, with plans for expansion involving an additional 23 clients either committed or in negotiations within just eight months since its launch.
Furthermore, the company is making strides in the acquisition space, with planned acquisitions of Carlisle Management and FCF Advisors, which are expected to contribute an impressive $2.6 billion in assets under management to Abacus's portfolio. Both acquisitions are anticipated to close by the end of the fourth quarter, pending regulatory approval.
Key Highlights from Q3 2024
Growth in Revenue and Investments
- Total revenue surged 33% compared to the previous year, reaching $28.1 million, driven by increased active management revenue and a higher volume of life insurance policies sold.
- Capital deployment for the quarter was $93.2 million, marking a substantial increase from $56.4 million year-over-year, along with a 54% rise in policy origination to 278 policies.
- GAAP net loss for the third quarter was reported at $5.1 million, primarily influenced by a non-cash warrant liability adjustment of $7.8 million. This compared to a net income of $0.9 million for the prior year.
- Adjusted net income soared 65% to $14.9 million, translating to adjusted earnings per share of $0.20, up from $0.14 a year ago.
- Adjusted EBITDA exhibited a sharp rise of 54%, reaching $16.7 million, with an adjusted EBITDA margin improving to 59.2% from 51.1% in the previous year.
- Return on Invested Capital (ROIC) for the quarter was recorded at 21%, while return on equity (ROE) stood at an impressive 23%.
Financial Stability and Growth Strategies
Liquidity Position
As of September 30, Abacus maintained a robust liquidity position with cash and equivalents amounting to $19.4 million and total policy assets valued at $274.4 million. Total outstanding long-term debt was reported at $166.5 million, reflecting the company’s strategic management of capital resources.
Future Outlook and New Technologies
Abacus Life continues to adapt and innovate in order to enhance its competitive edge within the market. The launch of PREADISAN™, a groundbreaking health prediction tool in partnership with Lorisco, demonstrates Abacus's commitment to utilizing advanced technology to deliver personalized financial solutions and longevity forecasting capabilities to its clients. As the year closes, the organization is well-placed to continue driving sustained growth and generating long-term value for its shareholders.
Frequently Asked Questions
What were Abacus Life's total revenues for Q3 2024?
Total revenues for Q3 2024 reached $28.1 million, reflecting a 33% increase year-over-year.
How much did adjusted net income grow?
Adjusted net income grew 65% year-over-year, amounting to $14.9 million in Q3 2024.
What strategic initiatives is Abacus Life currently focusing on?
Abacus Life is focusing on enhancing its ABL Tech platform, expanding its client base, and completing strategic acquisitions to increase its assets under management.
What is the expected impact of the Carlisle Management acquisition?
The acquisition of Carlisle Management is anticipated to add approximately $2.6 billion in assets under management to Abacus Life.
What technologies is Abacus Life developing?
Abacus Life has launched PREADISAN™, a health prediction tool designed to personalize financial solutions based on longevity data.
